概述
This guidance should be read in conjunction with the following NICE guidance:
NICE technology appraisal guidance 75 (TA75) 'Interferon alfa (pegylated and nonpegylated)
and ribavirin for the treatment of chronic hepatitis C' (which covers moderate
to severe hepatitis C)